Colorado Rocky Mountain Health Plans ESA Coverage Update | OpenPayer
ModifiedColorado Rocky Mountain Health PlansPolicy 2026D0028Y
Erythropoiesis-Stimulating Agents
Policy governing coverage and medical necessity criteria for erythropoiesis-stimulating agents (Aranesp, Epogen/Procrit, Mircera, Retacrit) for Colorado Rocky Mountain Health Plans members, including diagnosis-specific requirements and product-preference rules.
Added language to clarify Retacrit is the preferred ESA product for medical necessity plans.
Added language clarifying patient must meet Preferred Product Criteria for continuation of Epogen or Procrit therapy.
Updated CMS and References sections to reflect the most current information.
Retacrit preferredpreferred ESA product
Hct <30%typical hematocrit threshold
≤12 monthsauthorization period
unproven
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
Mircera stance
0.65RR transfusion (cancer)
Coverage and Medical Necessity Criteria
Anemia due to chronic kidney disease — patients receiving dialysis
ESAs are proven and medically necessary when ALL of the following are met:
ALL of the following
on_dialysis: Patient is on dialysis
hct_init: Hematocrit is less than 30% at initiation of therapy<30%
Initial authorization ≤12 months
exclude_other_causes: No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; patient is on dialysis; documentation of positive clinical response to ESA therapy; hematocrit remains less than 33%Hct <33%
Reauthorization ≤12 months
Anemia due to chronic kidney disease — patients not receiving dialysis
ESAs are proven and medically necessary when ALL of the following are met:
ALL of the following
not_on_dialysis: Patient is not on dialysis
hct_init: Hematocrit is less than 30% at initiation of therapy<30%
Initial authorization ≤12 months
rate_decline: Rate of hematocrit decline indicates likelihood of requiring RBC transfusion
Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary when ALL of the following are met:
ALL of the following
hct_init: Hematocrit less than or equal to 30% at initiation of therapy≤30%
Initial authorization ≤12 months
exclude_other_causes_and_iron_norm: No evidence of other causes of anemia and documentation of normal iron stores
one_of_indications: One of the following: patient has moderate to severe CKD; OR undergoing palliative treatment; OR receiving myelosuppressive chemotherapy not given with curative intent; OR receiving myelosuppressive chemotherapy with curative intent and patient refuses blood transfusion(s)
Anemia associated with myelodysplastic syndromes (MDS)
Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary when ALL of the following are met:
ALL of the following
epo_level: Serum erythropoietin level less than or equal to 500 mUnits/mL≤500 mUnits/mL
hct_init: Hematocrit less than or equal to 30% at initiation of therapy≤30%
Initial authorization ≤12 months
exclude_other_causes: No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
Anemia associated with myeloproliferative neoplasms — myelofibrosis
Aranesp, Epogen, Procrit, and Retacrit are proven and medically necessary when ALL of the following are met:
ALL of the following
epo_level: Serum erythropoietin level less than or equal to 500 mUnits/mL≤500 mUnits/mL
hct_init: Hematocrit less than or equal to 30% at initiation of therapy≤30%
Initial authorization ≤12 months
exclude_other_causes: No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
Anemia associated with zidovudine in HIV
Epogen, Procrit, and Retacrit are proven and medically necessary when ALL of the following are met:
ALL of the following
zidovudine_dose: Patient is receiving zidovudine administered at less than or equal to 4200 mg/week≤4200 mg/week
epo_level: Endogenous serum erythropoietin level less than or equal to 500 mUnits/mL≤500 mUnits/mL
hct_init: Hematocrit is less than 30% at initiation of therapy<30%
Initial authorization ≤12 months
Anemia associated with hepatitis C treatment (ribavirin + interferon)
Epogen, Procrit, and Retacrit are proven and medically necessary when ALL of the following are met:
ALL of the following
on_ribavirin_interferon: Patient is receiving ribavirin and interferon therapy
hct_init: Hematocrit less than or equal to 30% at initiation of therapy≤30%
Initial authorization ≤12 months
exclude_other_causes: No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
Preoperative use to reduce allogeneic transfusions (elective noncardiac, nonvascular surgery)
Epogen, Procrit, and Retacrit are proven and medically necessary perioperatively when ALL of the following are met:
ALL of the following
periop_hct: Perioperative hematocrit is greater than 30% and less than or equal to 39%>30% and ≤39%
Authorization ≤3 months
expected_blood_need: Patient expected to require at least 2 units of blood during the surgical procedure≥2 units
high_risk_blood_loss: Patient is at high risk for blood loss during surgery
Contexts where ESAs are unproven or require caution
Use of ESAs is unproven or associated with harm in the following situations or requires individualized risk-benefit consideration:
Unproven indications: Patients undergoing curative chemotherapy; patients receiving hormonal agents, biologic products, or radiotherapy alone (unless also receiving concomitant myelosuppressive chemotherapy); patients who require immediate correction of anemia as a substitute for RBC transfusions; patients undergoing cardiac or vascular surgery; patients scheduled for surgery who will donate autologous blood; patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure; patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion.
From policy unproven indications list
Oncology safety concerns: Randomized and meta-analytic data show ESAs reduce transfusion rates but are associated with increased thromboembolic events and increased mortality or decreased survival in certain cancer populations (e.g., metastatic breast cancer, head and neck cancer with radiation, lymphoid malignancy, non–small cell lung cancer, and patients not receiving chemotherapy/radiotherapy).
See Cochrane and meta-analysis findings
CKD safety concerns:
ESA use for cancer- and chemotherapy-induced anemia
Covered when ALL of the following are met
Cancer-related ESA criteria: 1) Anemia due to myelosuppressive chemotherapy for lymphoid malignancies or solid tumors OR specific hematologic conditions (MDS, myeloproliferative neoplasms); 2) Patient is receiving myelosuppressive therapy (not for patients not receiving therapy or receiving non-myelosuppressive therapy); 3) Use aligns with FDA‑approved indications/dosing and REMS where applicable; 4) Risks and benefits have been discussed with the patient and documented; 5) ESA is discontinued after completion of chemotherapy or if loss of response or antibody-mediated anemia occurs.
Reflects NCCN guidance
ESA use in chronic kidney disease (CKD)
Covered when criteria individualized per KDIGO guidance
CKD ESA initiation and maintenance: 1) Individualized decision balancing transfusion avoidance and symptom relief versus risks (stroke, hypertension, vascular access loss); 2) For adult CKD non‑dialysis (ND): generally do not initiate ESA if Hb ≥ 10.0 g/dL; if Hb < 10.0 g/dL, decision individualized based on rate of fall, iron status, transfusion risk, and symptoms; 3) For CKD stage 5D (dialysis): consider starting ESA when Hb is 9.0–10.0 g/dL to avoid falling below 9.0 g/dL; 4) Maintenance: generally avoid maintaining Hb >11.5 g/dL in adults and do not intentionally increase above 13 g/dL; pediatric targets differ.Hb thresholds per KDIGO
Includes dosing and monitoring guidance per KDIGO
Neonatal/preterm ESA use
Evidence summary and coverage stance
Neonatal outcomes: Early ESA initiation (<8 days) reduces use of ≥1 RBC transfusions (RR 0.79; NNTB 7) and NEC (RR 0.69; NNTB 33) but evidence quality ranges low to moderate; neurodevelopmental outcomes are heterogeneous and routine administration is not currently recommended.
Reflects Cochrane assessment
ESA therapy criteria and management
Coverage and management guidance for ESA therapy and monitoring
Monitoring requirements: Measure hemoglobin at least monthly during initiation; for CKD ND maintenance measure hemoglobin at least every 3 months; for CKD 5D maintenance measure hemoglobin at least monthly.see monitoring intervals
From Work Group recommendations
Definition of hyporesponsiveness: Initial hyporesponsiveness: no hemoglobin increase after first month on appropriate weight‑based dosing; Acquired hyporesponsiveness: after stable dosing, requires two increases up to 50% beyond prior stable dose to maintain hemoglobin.two increases up to 50%
Defines response classifications
Dose escalation limits for hyporesponsiveness: Avoid repeated escalations in ESA dose beyond double the initial weight‑based dose for initial hyporesponsiveness and beyond double the stable dose for acquired hyporesponsiveness.
The policy identifies multiple clinical contexts in which erythropoiesis‑stimulating agents (ESAs) are considered unproven or require individualized risk–benefit assessment. Key unproven contexts include patients undergoing curative‑intent myelosuppressive chemotherapy, patients receiving hormonal agents, biologic products, or radiotherapy alone (unless receiving concomitant myelosuppressive chemotherapy), and situations where immediate correction of anemia would substitute for an RBC transfusion. These determinations reflect evidence that, while ESAs reduce transfusion need in some settings, trials and meta‑analyses have shown increased thromboembolic events and worse survival outcomes in specific cancer populations, supporting caution or noncoverage in these groups.
For oncology patients, ESAs are not considered proven when the chemotherapy is given with curative intent; use in this group is generally unproven except in narrowly defined exceptions (for example, when a patient refuses blood transfusion). Similarly, ESAs are unproven for patients receiving only hormonal therapy, biologic agents, or radiotherapy (without concomitant myelosuppressive chemotherapy). These exclusions align with guideline and trial data cited in the policy and should guide claims and prior authorization decisions.
Use of ESAs for patients with cancer who are not receiving myelosuppressive therapy, who are receiving non‑myelosuppressive therapy, or who have an identified and treatable cause of anemia is considered off‑indication/unproven for the cancer‑specific coverage pathway. The policy requires that ESA use in cancer align with guidelines (e.g., NCCN) and be restricted to patients receiving myelosuppressive chemotherapy where applicable; requests outside these contexts may be denied.
The Work Group explicitly recommends not using androgens as an adjuvant to ESA therapy. This recommendation is cited as a formal guidance (1B) and is incorporated into the policy's management and adjuvant therapy statements; androgen co‑administration should not be used to enhance ESA response.
The policy highlights that ESAs in cancer settings have demonstrated a reduction in transfusion need but have also been associated with increased thromboembolic events and, in some trials, worse survival or progression‑free outcomes in particular cancer subgroups. Consequently, ESA use in many chemotherapy situations is considered unproven or requires individualized assessment of risks and benefits, with adherence to guideline recommendations (e.g., NCCN) when applied.
In general, uses listed as unproven in this policy are treated as not medically necessary absent compelling documentation supporting an exception. Where the evidence is uncertain or suggests harm, coverage decisions should follow the policy exclusions and require clear clinical justification and documentation when an exception is requested.
Routine administration of erythropoietin products in neonates is not recommended by the policy because available trials show heterogeneous results and limited overall benefit; darbepeotin requires further study. The policy therefore does not support routine neonatal ESA use pending results from larger trials.
The policy advises against initiating or maintaining ESA therapy with the intent to achieve hemoglobin above guideline‑recommended thresholds. Specifically, the KDIGO‑informed guidance notes generally avoiding maintenance of Hb concentrations above 11.5 g/dL in adults and not intentionally increasing Hb above 13 g/dL. For CKD non‑dialysis adults, initiating ESA when Hb is ≥ 10.0 g/dL is generally not suggested and requires individualized justification.
Mircera is considered unproven for the treatment of anemia due to cancer chemotherapy.
Policy explicitly states Mircera is unproven for this indication; use of other ESAs may be permitted per criteria and Preferred Product rules.
Evidence finding
Effect / magnitude
Management implication
ESA therapy reduces need for RBC transfusion
Relative risk of transfusion RR 0.65 (70 trials; n=16,093); mean ~1 unit less blood per patient in ESA group (19 trials)
Consider ESA when transfusion avoidance is an important clinical goal; weigh against harms and document informed consent and indication (e.g., palliative myelosuppressive chemotherapy).
Topic
Guidance
Clinical note
Initial dosing and dose adjustment
Determine initial ESA dose using patient Hb, body weight, and clinical circumstances; adjust dose based on Hb concentration, rate of Hb change, current ESA dose, and clinical circumstances.
Prefer dose reduction over withholding when downward adjustment is needed; re-evaluate dose with adverse events or hyporesponsiveness.
Applicable Codes and Measurement Thresholds
Applicable HCPCS/NDC drug codesHCPCS
J0881
Injection, darbepoetin alfa, 1 mcg (non-ESRD use)
J0882
Injection, darbepoetin alfa, 1 mcg (for ESRD on dialysis)
J0885
Injection, epoetin alfa, (for non-ESRD use), 1000 units
J0887
Injection, epoetin beta, 1 microgram, (for ESRD on dialysis)
Injection, epoetin alfa, 100 units (for ESRD on dialysis)
Q5105
Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for ESRD on dialysis), 100 units
Q5106
Injection, epoetin alfa-epbx, biosimilar, (Retacrit) (for non-ESRD use), 1000 units
Hematocrit (Hct) thresholds — initiation and continuation
Typical initiation thresholdHematocrit <30% is the usual threshold to initiate ESA therapy (applies across CKD, cancer chemotherapy, MDS, myelofibrosis, zidovudine- and hepatitis C–related anemia)
CKD on dialysis continuationFor patients on dialysis, hematocrit must remain <33% for continuation of therapy
CKD not on dialysis continuationFor patients not on dialysis, hematocrit must remain <30% for continuation of therapy
MDS/myelofibrosis/zidovudine/hepatitis C initiationHematocrit ≤30% at initiation for MDS, myelofibrosis, zidovudine-associated and ribavirin+interferon–related anemia
Perioperative use rangePerioperative hematocrit >30% and ≤39% for preoperative ESA use to reduce transfusions
Prior Authorization, Documentation, and Billing Guidance
Prior Authorization
Product preference / prior authorization
Retacrit is the preferred ESA product for Medical Necessity plans. Prior authorization is not required for Retacrit. Coverage for Epogen or Procrit is contingent on meeting the Preferred Product Criteria; members already receiving Epogen or Procrit may be required to switch to Retacrit for continuation of therapy unless they meet the Preferred Product Criteria below. Failure to follow the Preferred Product Criteria may result in non-coverage or claim denial.
Retacrit preferred; no PA required for Retacrit
Epogen/Procrit continuation requires meeting Preferred Product Criteria or documented exception
Non-adherence to Preferred Product Criteria may lead to denial
Billing Rule
Drug codes and benefit/PA reminder
Line of Therapy and Treatment Positioning
LINE OF THERAPY
1 top-level node
ANY of the following
palliative_or_noncurative_chemo: Receiving myelosuppressive chemotherapy not given with curative intent
Eligible
curative_chemo_refuse_transfusion: Receiving myelosuppressive chemotherapy with curative intent AND patient refuses blood transfusion(s)
Eligible
any
1 top-level node
Oncology setting considerations:
Laboratory and Biomarker Criteria
Serum erythropoietin (biomarker requirement)
Biomarker thresholdSerum erythropoietin ≤500 mUnits/mL is required for MDS, myelofibrosis, and zidovudine-associated anemia indications
Applied at initiation and continuationEPO ≤500 mUnits/mL must be documented at initiation and for continuation reassessments
Used with hematocrit criteriaEPO threshold is used alongside Hct ≤30% at initiation and disease‑specific continuation Hct cutoffs
Definitions and Diagnostic Criteria
Hematocrit conversion guidance
Hematocrit estimation methodEstimate Hct by multiplying hemoglobin by 3 (Hgb × 3 ≈ Hct) when only Hgb is available
Common exampleHgb 10 g/dL ≈ Hct 30% (used for claims and eligibility)
Documentation usePolicy instructs using this conversion for clinical documentation and claim submission when Hct not directly measured
ESAs — named agents referenced
Named agents in policyAranesp (darbepoetin alfa), Epogen/Procrit (epoetin alfa), Mircera (methoxy polyethylene glycol–epoetin beta), Retacrit (epoetin alfa biosimilar)
Preferred product noteRetacrit is specified as the preferred ESA product for medical necessity plans
Background and Evidence Summary
Background: Erythropoiesis‑stimulating agents (ESAs) are recombinant or modified erythropoietic proteins (e.g., epoetin alfa, darbepoetin alfa, continuous erythropoietin receptor activators) used to treat anemia from multiple causes including chronic kidney disease (with or without dialysis), chemotherapy‑related myelosuppression, myelodysplastic syndromes, myeloproliferative disorders, zidovudine‑associated anemia, hepatitis C therapy–related anemia, and in selected perioperative settings to reduce allogeneic transfusions. Their use requires consideration of indication‑specific thresholds, monitoring requirements, and safety concerns described elsewhere in the policy.
Billing, Monitoring, and Safety Monitoring
Clinical justification and lab documentation
Clinical justification requiredPrior authorization and claims should document the clinical indication and relevant labs (hemoglobin or hematocrit) supporting ESA use
Hct timing for claimsHematocrit reported with professional claims (CMS-1500/837P) must be from within 30 days of the injection
Documentation elementsInclude evaluation excluding other anemia causes (iron deficiency, hemolysis, B12 deficiency) and prior trials of preferred product when applicable
Monitoring intervals and PRCA evaluation timing
Monitoring intervalsMeasure Hb monthly during initiation; for CKD ND maintenance measure Hb every 3 months; for CKD 5D maintenance measure Hb monthly
PRCA evaluation timing
Policy Changes and Revision History
2026-04-01revisionLatest
Added language clarifying Retacrit is the preferred ESA product for medical necessity plans and that continuation of Epogen or Procrit requires meeting the policy's Preferred Product Criteria; archived prior version 2025D0028X.
No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; patient is not on dialysis; documentation of positive clinical response to ESA therapy; therapeutic goal is reducing transfusion risks; hematocrit remains less than 30%Hct <30%
Reauthorization ≤12 months
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; documentation of positive clinical response; hematocrit remains less than or equal to 30%≤30%
Reauthorization ≤12 months
ipss_risk: Treatment for lower risk disease (IPSS‑R Very Low, Low, Intermediate) with symptomatic anemia
cytogenetics_and_rs: Either del(5q) OR (without del(5q) AND ring sideroblasts <15% (or <5% with SF3B1 mutation)) OR (without del(5q) AND ring sideroblasts ≥15% (or ≥5% with SF3B1) after no response to Reblozyl)
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; documentation of positive clinical response; serum erythropoietin ≤500 mUnits/mL; hematocrit remains less than or equal to 36%Hct ≤36%
Reauthorization ≤12 months
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; documentation of positive clinical response; serum erythropoietin ≤500 mUnits/mL; hematocrit remains less than or equal to 36%Hct ≤36%
Reauthorization ≤12 months
exclude_other_causes: No evidence of other causes of anemia (e.g., iron deficiency, hemolysis, vitamin B12 deficiency)
continuation_rules: For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; documentation of positive clinical response; patient remains on zidovudine ≤4200 mg/week; endogenous serum erythropoietin ≤500 mUnits/mL; hematocrit remains less than or equal to 36%Hct ≤36%
Reauthorization ≤12 months
continuation_rules:
For continuation: if the request is for Epogen or Procrit, patient meets the Preferred Product Criteria; documentation of positive clinical response; patient remains on ribavirin and interferon therapy; hematocrit remains less than or equal to 36%
Hct ≤36%
Reauthorization ≤12 months
unable_unwilling_autologous: Patient is unable or unwilling to donate autologous blood
surgery_type: Elective, noncardiac, nonvascular surgery
Higher hematocrit/hemoglobin targets achieved with ESAs in CKD/dialysis have been associated with increased mortality and cardiovascular events (including stroke); trial evidence (e.g., TREAT) shows increased stroke risk at higher targets.
Trial evidence summarized
Surgery context: Perioperative ESA use reduced transfusion rates in some trials but had associated higher thrombotic event rates in others; cost-effectiveness concerns exist for elective orthopedic surgery.
Trial heterogeneity noted
Neonatal/infant outcomes: Early ESAs in preterm/low birth weight infants reduced RBC transfusions and some neonatal complications (IVH, PVL, NEC) but evidence quality varies and routine administration is not currently recommended pending larger trials.
Cochrane reviews summarized
≤ 2× prior dose
Work Group suggestion (2D)
Management of poor response: Evaluate and treat specific causes of poor response; if hyporesponsive despite correction, individualize therapy considering hemoglobin decline, continued ESA use versus transfusion, and doses required.clinical judgment
Not graded guidance
Adjuvant therapies: Do not use androgens as an adjuvant to ESA; the Work Group also suggests not using vitamin C, vitamin D, vitamin E, folic acid, L‑carnitine, or pentoxifylline as ESA adjuvants.N/A
Recommendations vary (1B/2D)
PRCA evaluation and action: Investigate for antibody‑mediated PRCA in patients on ESA >8 weeks who develop rapid hemoglobin decline (≈0.5–1.0 g/dl/week) with normal platelets/WBC and absolute reticulocyte count <10,000/µl; stop ESA if antibody‑mediated PRCA is diagnosed; peginesatide recommended to treat antibody‑mediated PRCA.>8 weeks on ESA
Recommendation levels 1A/1B
Product selection: Choose ESA based on pharmacodynamics, safety, clinical outcomes, costs, and availability; use regulatory agency–approved ESAs and true biosimilars for copy versions.regulatory approval
Work Group recommendation (1D/2D)
Serum erythropoietin requirement
Required serum EPO levelSerum erythropoietin ≤500 mUnits/mL is required for MDS, myelofibrosis, and zidovudine-associated anemia
Continuation requirementFor continuation in MDS, myelofibrosis, and zidovudine-associated anemia, serum erythropoietin must remain ≤500 mUnits/mL
Contextual applicationsEPO ≤500 mUnits/mL is applied alongside Hct ≤30% at initiation and other disease-specific criteria
Hemoglobin-to-hematocrit conversion guidance
Conversion factorUse Hgb × 3 ≈ Hct to estimate hematocrit when only hemoglobin measured (e.g., Hgb 10 g/dL ≈ Hct 30%)
Claim submission noteWhen submitting ESA claims on CMS-1500/837P include Hct (or Hgb converted to Hct) from within 30 days of injection
Hemoglobin thresholds and initiation cautions
NCCN/KDIGO hemoglobin considerationsRefer to NCCN for evaluation at Hgb ≤11 g/dL or ≥2 g/dL below baseline; KDIGO advises not initiating ESA in CKD ND adults with Hb ≥10.0 g/dL and not intentionally increasing Hb above 13 g/dL
Cancer-specific thresholdNCCN guidance applies to patients with Hgb ≤11 g/dL or ≥2 g/dL below baseline in oncology settings
CKD maintenance targetKDIGO: generally avoid maintaining Hb >11.5 g/dL in adults; do not intentionally increase above 13 g/dL
Initiation cautionFor CKD ND adults, initiation should be individualized when Hb <10.0 g/dL; do not start at Hb ≥10.0 g/dL except individualized cases
Reticulocyte count threshold in PRCA evaluation
Reticulocyte absolute count thresholdAbsolute reticulocyte count <10,000/µl is a criterion when evaluating for antibody-mediated PRCA
Associated labsPRCA evaluation also requires assessment of platelets and white blood cell counts (should be normal)
Timing contextConsider this reticulocyte threshold in patients on ESA therapy for >8 weeks with rapid Hb decline
Rate of hemoglobin decline indicating PRCA
Rate of Hb decline suggesting PRCAA sudden rapid Hb decrease of 0.5–1.0 g/dL per week suggests possible antibody‑mediated PRCA and warrants evaluation
Associated transfusion rateMay be accompanied by need for transfusions at about 1–2 units per week
Context for concernEvaluate for PRCA in patients receiving ESA >8 weeks who meet these decline criteria with normal platelets/WBC and low reticulocyte count
Use the HCPCS/J-codes and biosimilar Q-codes listed when submitting claims. Benefit coverage and prior authorization requirements vary by member plan and may be affected by state mandates — consult the member's benefit document and applicable laws.
Benefit and PA requirements depend on the member-specific plan and state mandates
Denial Risk
CKD on dialysis Hct threshold
For patients on dialysis, ESA therapy initiation is considered medically necessary only when the hematocrit is less than 30%. Continuation of ESA therapy is supported only while hematocrit remains less than 33%. Requests with hematocrit greater than or equal to 33% are considered unproven/not covered.
Initiation threshold (CKD on dialysis): Hct < 30%
Continuation threshold (CKD on dialysis): Hct < 33%
Hct ≥ 33% in dialysis patients — ESA use is unproven/not covered
Denial Risk
CKD not on dialysis Hct threshold
For patients not receiving dialysis, initiation of ESA therapy is considered medically necessary only when hematocrit is less than 30% and other clinical criteria are met (e.g., rate of decline indicating likely need for transfusion). Continuation of therapy requires hematocrit remain less than 30%. Hematocrit greater than 30% in non-dialysis CKD patients is considered unproven/not covered.
Initiation threshold (CKD not on dialysis): Hct < 30%
Continuation threshold (CKD not on dialysis): Hct < 30%
Hct > 30% in non-dialysis patients — ESA use is unproven/not covered
ESA use is considered unproven for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure or when anemia can be managed with transfusion. ESAs should not be used in these settings absent compelling justification.
ESAs unproven for curative-intent chemotherapy
ESAs unproven when anemia can be managed by transfusion
Documentation Required
Claim documentation requirement
Professional/physician claims (1500 form / 837P) for ESA administration must include a hematocrit level obtained within 30 days of the injection. Failure to submit required Hct documentation with the claim may result in processing delays or denial.
Submit Hct level on 1500/837P claims within 30 days of injection
Hct requirement applies to ESA claims for accurate adjudication
Denial Risk
Off-indication use
ESAs used outside the indications and coverage criteria in this policy are considered unproven and may not be covered. Consult the Diagnosis-Specific Criteria and member benefits before prescribing or billing for off-indication uses.
Off-indication ESA use is not covered unless evidence supports medical necessity and benefit plan/state mandates apply
Denial Risk
CKD initiation threshold
For CKD non-dialysis adults the guideline suggests not initiating ESA therapy when hemoglobin is ≥ 10.0 g/dL; initiation decisions should be individualized below that threshold considering rate of decline, iron response, transfusion risk, and symptoms.
Do not initiate ESA in adult CKD ND patients with Hb ≥ 10.0 g/dL except in individualized cases
Individualize initiation when Hb < 10.0 g/dL based on clinical factors
Documentation Required
Required clinical documentation
Required clinical documentation for prior authorization and continuation requests includes hematocrit or hemoglobin values (with dates), evaluation excluding other causes of anemia (iron studies, B12, hemolysis workup), prior therapies and response (including trial of Retacrit when applicable), documentation of positive clinical response to ESA therapy for continuation, and evidence of counseling on risks/benefits.
Hct/Hb values with dates (pretreatment and on-therapy as applicable)
Iron studies and evaluation excluding other causes of anemia
Documentation of prior therapies and response (including Retacrit trial or failure if Epogen/Procrit requested)
For continuation: documentation of positive clinical response to ESA
Counseling/informed decision documentation regarding risks of ESA therapy
Documentation Required
Hematocrit reporting and conversion guidance
If only hemoglobin is reported, use a conversion factor of 3 to estimate hematocrit for claims and clinical decision-making (Hgb x 3 ≈ Hct). Examples: Hgb 10 g/dL ≈ Hct 30%; Hgb 11 g/dL ≈ Hct 33%; Hgb 12 g/dL ≈ Hct 36%.
Hct estimate = Hgb × 3 (use when only Hgb available)
Benefit coverage for ESAs may vary by member certificate and by state law. Some plans may cover experimental or off-label uses under specific circumstances; state mandates may require coverage for certain off-label uses. Always consult the member-specific benefit document and applicable state regulations when making coverage determinations.
Member-specific benefit document and state mandates determine coverage applicability
Where state mandates apply, they supersede benefit language and policy statements
Step Therapy
Optimize iron/alternative therapy first
Optimize iron stores and consider alternative or adjunctive therapies before initiating ESA therapy when appropriate. Document iron repletion efforts and response prior to ESA initiation except when contraindicated.
Assess and optimize iron status before ESA initiation
Document iron therapy and response in the medical record and prior authorization materials
Note
Product selection guidance
Select erythropoiesis-stimulating agents that are approved by a regulatory authority. For copy versions, use true biosimilar products rather than non-comparable copies. Consider pharmacodynamics, safety, clinical outcomes, costs, and availability when choosing an ESA.
Use regulatory-approved ESAs; for copy versions, use true biosimilars
Select ESA based on safety, outcomes, cost, and availability
ESAs may be used to reduce transfusion requirements in cancer patients receiving myelosuppressive chemotherapy but are unproven or contraindicated in patients receiving curative‑intent chemotherapy, patients receiving hormonal/biologic/radiation therapy alone, and where anemia can be managed by transfusion; ESA use requires consideration of increased thromboembolic and mortality risks in certain cancer subpopulations.
Evidence from Cochrane and trials
first-line | subsequent
1 top-level node
Chemotherapy-related indication: ESA use limited to anemia due to myelosuppressive chemotherapy; consider treatment intent (curative vs palliative) and avoid ESA when intent is curative unless exceptions per guidance are met.
Mircera coverage stanceMircera is considered unproven for treatment of cancer chemotherapy–related anemia
Erythropoiesis‑stimulating agents — definition
DefinitionErythropoiesis-stimulating agents (ESAs) are recombinant or modified proteins (e.g., epoetin alfa, darbepoetin alfa, methoxy polyethylene glycol–epoetin beta) that stimulate red blood cell production via the erythropoietin receptor
Clinical use summaryUsed to treat anemia from CKD, cancer chemotherapy, MDS, myelofibrosis, HIV zidovudine-associated anemia, hepatitis C therapy–related anemia, and perioperative reduction of transfusions
Agent differencesMolecular modifications (e.g., additional carbohydrate chains, PEGylation) alter half-life and receptor activity among agents
DefinitionMyelosuppressive chemotherapy–related anemia is anemia occurring in patients receiving chemotherapy that suppresses bone marrow function, for which ESA use may be recommended in selected settings per guidelines
Oncology criteriaESA use is limited to patients receiving myelosuppressive chemotherapy (typically not for curative-intent chemotherapy unless exceptions apply)
Guideline referenceRefer to NCCN Hematopoietic Growth Factors guidance for evaluation when Hgb ≤11 g/dL or ≥2 g/dL below baseline
ESA hyporesponsiveness — initial and acquired
Initial hyporesponsivenessNo increase in Hb after the first month of appropriate weight‑based ESA dosing defines initial hyporesponsiveness
Acquired hyporesponsivenessRequires two increases in ESA dose up to 50% beyond the previously stable dose to maintain Hb
Dose escalation guidanceAvoid repeated escalations beyond double the initial or prior stable dose when hyporesponsiveness occurs
PRCA suspicion criteria
PRCA suspicion triadSuspect antibody‑mediated PRCA in patients on ESA >8 weeks with: rapid Hb decline (0.5–1.0 g/dL per week), absolute reticulocyte count <10,000/µl, and normal platelets/WBC
Action on diagnosisInvestigate for PRCA and stop ESA if antibody‑mediated PRCA is diagnosed; consider peginesatide for treatment
Monitoring contextApply these criteria when monitoring patients monthly during initiation and per maintenance intervals thereafter
Investigate for antibody‑mediated PRCA in patients receiving ESA >8 weeks who develop rapid Hb decline, normal platelets/WBC, and reticulocyte <10,000/µl
Documentation of monitoringDocument Hb concentrations at the required intervals and document evaluation for PRCA when criteria are met